ClinicaliQ Trial Snapshot
- Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer — Active Not Recruiting • Phase III • Oncology • NCT04464226.
- Ongoing access to darolutamide for prostate cancer patients who benefited from previous trials, with continued monitoring.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study. Conditions: Cancer Interventions: Darolutamide (Nubeqa, BAY1841788) Lead Sponsor: Bayer Planned…